Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13757
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYeo, Dannel-
dc.contributor.authorHuynh, Nhi-
dc.contributor.authorBeutler, John A-
dc.contributor.authorBaldwin, Graham S-
dc.contributor.authorHe, Hong-
dc.contributor.authorNikfarjam, Mehrdad-
dc.date2016-03-30-
dc.date.accessioned2016-04-06T01:04:14Z-
dc.date.accessioned2016-04-06T01:04:23Z-
dc.date.available2016-04-06T01:04:14Z-
dc.date.available2016-04-06T01:04:23Z-
dc.date.issued2016-12-
dc.identifier.citationJournal of Investigative Surgery 2016; 29(6): 366-372en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13757-
dc.description.abstractBACKGROUND: Pancreatic cancer continues to have a poor survival rate with an urgent need for improved treatments. Glaucarubinone, a natural product first isolated from the seeds of the tree Simarouba glauca, has recently been recognized as having anti-cancer properties that may be particularly applicable to pancreatic cancer. METHODS: The effect of glaucarubinone on the growth and migration of murine pancreatic cancer cells was assessed by 3H-thymidine incorporation assay. The survival impact of glaucarubinone alone and in combination with gemcitabine chemotherapy was assessed using an immunocompetent orthotopic murine model of pancreatic cancer. RESULTS: Glaucarubinone inhibited the growth of the murine pancreatic cancer cell lines LM-P and PAN02. Treatment with either glaucarubinone or gemcitabine reduced proliferation in vitro and the combination was synergistic. The combination treatment improved survival two-fold compared to gemcitabine treatment alone (p = 0.046) in PAN02 cells. CONCLUSIONS: The synergistic inhibition by glaucarubinone and gemcitabine observed in vitro and the improved survival in vivo suggest that glaucarubinone may be a useful adjunct to current chemotherapy regimensen_US
dc.subjectGemcitabineen_US
dc.subjectGlaucarubinoneen_US
dc.subjectProstatic Neoplasmsen_US
dc.titleGlaucarubinone combined with gemcitabine improves pancreatic cancer survival in an immunocompetent orthotopic murine modelen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Investigative Surgeryen_US
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationMolecular Targets Laboratory, National Cancer Institute, Frederick, MD, USAen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27027695en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-0944-8747-
dc.identifier.orcid0000-0003-4866-276X-
dc.type.austinJournal Articleen_US
local.name.researcherHe, Hong
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.